- Home
- MIRM vs ETY Comparison
MIRM vs ETY Comparison
Compare MIRM & ETY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- ETY
- Stock Information
- Founded
- MIRM 2018
- ETY 2006
- Country
- MIRM United States
- ETY United States
- Employees
- MIRM N/A
- ETY N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- ETY Finance Companies
- Sector
- MIRM Health Care
- ETY Finance
- Exchange
- MIRM Nasdaq
- ETY Nasdaq
- Market Cap
- MIRM 1.9B
- ETY 2.1B
- IPO Year
- MIRM 2019
- ETY N/A
- Fundamental
- Price
- MIRM $44.27
- ETY $14.26
- Analyst Decision
- MIRM Strong Buy
- ETY
- Analyst Count
- MIRM 10
- ETY 0
- Target Price
- MIRM $60.80
- ETY N/A
- AVG Volume (30 Days)
- MIRM 425.9K
- ETY 247.3K
- Earning Date
- MIRM 05-07-2025
- ETY 01-01-0001
- Dividend Yield
- MIRM N/A
- ETY 7.21%
- EPS Growth
- MIRM N/A
- ETY N/A
- EPS
- MIRM N/A
- ETY N/A
- Revenue
- MIRM $379,251,000.00
- ETY N/A
- Revenue This Year
- MIRM $29.51
- ETY N/A
- Revenue Next Year
- MIRM $20.27
- ETY N/A
- P/E Ratio
- MIRM N/A
- ETY N/A
- Revenue Growth
- MIRM 69.31
- ETY N/A
- 52 Week Low
- MIRM $23.83
- ETY $10.59
- 52 Week High
- MIRM $54.23
- ETY $13.46
- Technical
- Relative Strength Index (RSI)
- MIRM 56.45
- ETY 58.79
- Support Level
- MIRM $40.00
- ETY $13.99
- Resistance Level
- MIRM $47.43
- ETY $14.37
- Average True Range (ATR)
- MIRM 2.07
- ETY 0.25
- MACD
- MIRM 0.54
- ETY 0.12
- Stochastic Oscillator
- MIRM 65.27
- ETY 92.99
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About ETY Eaton Vance Tax-Managed Diversified Equity Income Fund of Beneficial Interest
Eaton Vance Tax-mgd Dvsf Eq Inc Fd is a diversified, closed-end management investment company. Its primary investment objective is to provide current income and gains. The secondary objective of the fund is capital appreciation. Its portfolio of investments consists of capital markets, banks, internet and direct marketing retail, biotechnology, media, oil, gas, and consumable fuels, and other sectors.